PT - JOURNAL ARTICLE AU - Preto, António José AU - Chanana, Shaurya AU - Ence, Daniel AU - Healy, Matt D. AU - Domingo-Fernández, Daniel AU - West, Kiana A. TI - Multi-omics data integration identifies novel biomarkers and patient subgroups in inflammatory bowel disease AID - 10.1101/2024.07.23.24310846 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.23.24310846 4099 - http://medrxiv.org/content/early/2024/07/24/2024.07.23.24310846.short 4100 - http://medrxiv.org/content/early/2024/07/24/2024.07.23.24310846.full AB - Objective In this work, we explored one of the largest multi-omics cohorts in Inflammatory Bowel Disease (IBD), the Study of a Prospective Adult Research Cohort (SPARC IBD), with the goal of identifying predictive biomarkers for Crohn’s Disease (CD) and Ulcerative Colitis (UC) and elucidating patient subtypes.Design We analyzed genomics, transcriptomics (gut biopsy samples), and proteomics (blood plasma) from hundreds of patients from SPARC IBD. We trained a machine learning model that classifies UC vs. CD samples. In parallel, we leveraged multi-omics data integration to unveil patient subgroups in each of the two indications independently and analyzed the molecular phenotypes of these patient subpopulations.Results The high performance of the model showed that multi-omics signatures are able to discriminate between the two indications. The most predictive features of the model, both known and novel omics signatures for IBD, can potentially be used as diagnostic biomarkers. Patient subgroups analysis in each indication uncovered omics features associated with disease severity in UC patients, and with tissue inflammation in CD patients. This culminates with the observation of two CD subpopulations characterized by distinct inflammation profiles.Conclusion Our work unveiled potential biomarkers to discriminate between CD and UC and to stratify each population into well-defined subgroups, offering promising avenues for the application of precision medicine strategies.Competing Interest StatementAll authors were employees of Enveda Biosciences Inc. during the course of this work and have real or potential ownership interest in the company. Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Crohn’s & Colitis Foundation (CCF)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSPARC IBD is available upon approved application to Crohn’s & Colitis Foundation IBD Plexus (https://www.crohnscolitisfoundation.org/ibd-plexus). We released the scripts and notebooks to reproduce the work at https://github.com/enveda/sparc-multiomics.https://github.com/enveda/sparc-multiomicshttps://www.crohnscolitisfoundation.org/ibd-plexus